Precipio, Inc. (PRPO)
NASDAQ: PRPO · Real-Time Price · USD
6.26
+0.29 (4.87%)
At close: Mar 28, 2025, 4:00 PM
5.97
-0.29 (-4.64%)
After-hours: Mar 28, 2025, 4:05 PM EDT
Precipio Revenue
In the year 2024, Precipio had annual revenue of $18.53M with 21.95% growth. Precipio had revenue of $5.45M in the quarter ending December 31, 2024, with 25.90% growth.
Revenue (ttm)
$18.53M
Revenue Growth
+21.95%
P/S Ratio
0.50
Revenue / Employee
$325,123
Employees
57
Market Cap
9.28M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.53M | 3.34M | 21.95% |
Dec 31, 2023 | 15.20M | 5.79M | 61.46% |
Dec 31, 2022 | 9.41M | 563.00K | 6.36% |
Dec 31, 2021 | 8.85M | 2.76M | 45.26% |
Dec 31, 2020 | 6.09M | 2.97M | 94.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PRPO News
- 14 days ago - Precipio Announces Q4 and year-end 2024 Shareholder Update Call - GlobeNewsWire
- 4 weeks ago - Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited) - GlobeNewsWire
- 2 months ago - Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs - GlobeNewsWire
- 4 months ago - Precipio, Inc. (PRPO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Precipio Announces Q3-2024 Shareholder Update Call - GlobeNewsWire
- 6 months ago - Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping - GlobeNewsWire
- 7 months ago - Precipio Announces Employee Stock Option Plan Repricing - GlobeNewsWire
- 8 months ago - Precipio, Inc. (PRPO) Q2 2024 Earnings Call Transcript - Seeking Alpha